Jonna Ahl

2.3k total citations
70 papers, 1.7k citations indexed

About

Jonna Ahl is a scholar working on Psychiatry and Mental health, Pharmacology and Ecology. According to data from OpenAlex, Jonna Ahl has authored 70 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Psychiatry and Mental health, 23 papers in Pharmacology and 16 papers in Ecology. Recurrent topics in Jonna Ahl's work include Schizophrenia research and treatment (17 papers), Crustacean biology and ecology (14 papers) and Treatment of Major Depression (13 papers). Jonna Ahl is often cited by papers focused on Schizophrenia research and treatment (17 papers), Crustacean biology and ecology (14 papers) and Treatment of Major Depression (13 papers). Jonna Ahl collaborates with scholars based in United States, United Kingdom and Canada. Jonna Ahl's co-authors include Hans Laufer, H. Laufer, Amir Sagi, William J. Biggers, Madelaine M. Wohlreich, Bruce J. Kinon, John P. Houston, Paula J. Gaynor, Hong Liu‐Seifert and Lesley M. Arnold and has published in prestigious journals such as Neurology, Annals of the New York Academy of Sciences and Journal of Affective Disorders.

In The Last Decade

Jonna Ahl

68 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonna Ahl United States	24	771	390	367	335	311	70	1.7k
Vincenzo Di Stefano Italy	25	257 0.3×	390 1.0×	88 0.2×	105 0.3×	91 0.3×	138	2.0k
David J. Allsop Australia	17	180 0.2×	117 0.3×	685 1.9×	207 0.6×	51 0.2×	30	1.1k
Yasuhiro Ueno Japan	31	144 0.2×	194 0.5×	89 0.2×	326 1.0×	67 0.2×	174	2.6k
William G. Clark United States	22	125 0.2×	277 0.7×	92 0.3×	275 0.8×	164 0.5×	61	2.2k
Lorenzo Lorusso Italy	19	857 1.1×	46 0.1×	132 0.4×	129 0.4×	50 0.2×	88	1.7k
James A. Cooper United Kingdom	17	428 0.6×	244 0.6×	158 0.4×	230 0.7×	13 0.0×	53	1.7k
D. Rice Canada	16	136 0.2×	57 0.1×	87 0.2×	359 1.1×	98 0.3×	26	2.9k
Ola Svensson Sweden	25	176 0.2×	461 1.2×	248 0.7×	44 0.1×	70 0.2×	77	2.0k
Mark S. Brownfield United States	33	101 0.1×	100 0.3×	91 0.2×	964 2.9×	103 0.3×	63	2.6k
Michaela Poppe United Kingdom	20	308 0.4×	371 1.0×	78 0.2×	90 0.3×	14 0.0×	39	1.6k

Countries citing papers authored by Jonna Ahl

Since Specialization

Citations

This map shows the geographic impact of Jonna Ahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonna Ahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonna Ahl more than expected).

Fields of papers citing papers by Jonna Ahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonna Ahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonna Ahl. The network helps show where Jonna Ahl may publish in the future.

Co-authorship network of co-authors of Jonna Ahl

This figure shows the co-authorship network connecting the top 25 collaborators of Jonna Ahl. A scholar is included among the top collaborators of Jonna Ahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonna Ahl. Jonna Ahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aurora, Sheena K., Tina M. Oakes, Qi Zhang, Jonna Ahl, & James M. Martinez. (2017). Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab (P2.177). Neurology. 88(16_supplement). 1 indexed citations

Nery, Emel Serap Monkul, Mark E. Bangs, Peng Liu, Jonna Ahl, & David Pérahia. (2017). Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 27(8). 700–707. 4 indexed citations

Oakes, Tina M., et al.. (2015). Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Current Medical Research and Opinion. 31(6). 1179–1189. 8 indexed citations

Fijal, Bonnie A., Yingying Guo, Jonna Ahl, et al.. (2015). CYP2D6 predicted metabolizer status and safety in adult patients with attention‐deficit hyperactivity disorder participating in a large placebo‐controlled atomoxetine maintenance of response clinical trial. The Journal of Clinical Pharmacology. 55(10). 1167–1174. 18 indexed citations

Williamson, Owen D., et al.. (2014). Onset of Response with Duloxetine Treatment in Patients with Osteoarthritis Knee Pain and Chronic Low Back Pain: A Post Hoc Analysis of Placebo-Controlled Trials. Clinical Therapeutics. 36(4). 544–551. 11 indexed citations

Ahl, Jonna, Mark E. Bangs, Yingkai Cheng, et al.. (2013). The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthcare and Patient Safety. 5. 211–211. 15 indexed citations

Oakes, Tina M., Lauren B. Marangell, Jonna Ahl, et al.. (2012). Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Human Psychopharmacology Clinical and Experimental. 27(1). 47–56. 34 indexed citations

Houston, John P., Kurt Kroenke, Douglas E. Faries, et al.. (2011). A Provisional Screening Instrument for Four Common Mental Disorders in Adult Primary Care Patients. Psychosomatics. 52(1). 48–55. 23 indexed citations

Arnold, Lesley M., Fujun Wang, Jonna Ahl, Paula J. Gaynor, & Madelaine M. Wohlreich. (2011). Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Research & Therapy. 13(3). R86–R86. 36 indexed citations

10.

Houston, John P., Kurt Kroenke, Jonathan Davidson, et al.. (2011). PDI-4A: An Augmented Provisional Screening Instrument Assessing 5 Additional Common Anxiety-Related Diagnoses in Adult Primary Care Patients. Postgraduate Medicine. 123(5). 89–95. 7 indexed citations

11.

Clauw, Daniel J., et al.. (2010). Flexible dosed duloxetine versus placebo in the treatment of fibromyalgia: a randomized, double-blind trial. Journal of Pain. 11(4). S38–S38. 1 indexed citations

12.

Arnold, Lesley M., Daniel J. Clauw, Madelaine M. Wohlreich, et al.. (2009). Efficacy of Duloxetine in Patients With Fibromyalgia. The Primary Care Companion to The Journal of Clinical Psychiatry. 11(5). 237–244. 72 indexed citations

13.

Deberdt, Walter, Alan P. Siegal, Jonna Ahl, Adam L. Meyers, & Ronald Landbloom. (2007). Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis. International Journal of Geriatric Psychiatry. 23(4). 364–369. 8 indexed citations

14.

Battaglia, John, John P. Houston, Jonna Ahl, Adam L. Meyers, & Christopher Kaiser. (2005). A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clinical Therapeutics. 27(10). 1612–1618. 5 indexed citations

15.

Kennedy, John, Walter Deberdt, Alan P. Siegal, et al.. (2005). Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry. 20(11). 1020–1027. 33 indexed citations

16.

Houston, John P., et al.. (2005). Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: Post hoc analysis of patients treated with olanzapine or lithium. Journal of Psychiatric Research. 41(7). 616–621. 14 indexed citations

17.

Kinon, Bruce J., Hong Liu‐Seifert, Jonna Ahl, Saeeduddin Ahmed, & Robert W. Baker. (2004). Longitudinal Effect of Olanzapine on Fasting Serum Lipids: A Randomized, Prospective, 4‐Month Study. Annals of the New York Academy of Sciences. 1032(1). 295–296. 6 indexed citations

18.

Kinon, Bruce J., Jonna Ahl, Virginia L. Stauffer, Angela Hill, & P.F. Buckley. (2004). Dose Response and Atypical Antipsychotics in Schizophrenia. CNS Drugs. 18(9). 597–616. 44 indexed citations

19.

Laufer, Hans, William J. Biggers, & Jonna Ahl. (1998). Stimulation of Ovarian Maturation in the CrayfishProcambarus clarkiiby Methyl Farnesoate. General and Comparative Endocrinology. 111(2). 113–118. 151 indexed citations

20.

Awad, Issam A., Elaine Wyllie, H. Lüders, & Jonna Ahl. (1990). Intraoperative determination of the extent of corpus callosotomy for epilepsy. Neurosurgery. 26(1). 102–102. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact